Results 31 to 40 of about 4,254 (200)
Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy [PDF]
Endocrinology and MetabolismBackground Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab.
Sung Hye Kong +6 more
doaj +1 more source
Comparison of 18F-NaF Imaging, 99mTc-MDP Scintigraphy, and 18F-FDG for Detecting Bone Metastases
World Journal of Nuclear Medicine, 2022 Bone is a common metastasis site in several malignancies, most importantly prostate and breast cancers. Given the significance of the early and accurate diagnosis of bone metastases for preliminary staging, treatment planning and monitoring, restaging ...
Habibollah Dadgar +7 more
doaj +1 more source
The World Journal of Men's Health, 2022 Patients with prostate cancer (PCa) on androgen-deprivation therapy (ADT) are at high risk of osteoporosis and fragility fractures. We aimed to provide some practical insights into the delivery of optimal bone health care for PCa patients, particularly
Enrique Casado +5 more
doaj +1 more source
Rational Design of New Bright Luminescent Zinc Diphosphonates with 12-Member Ring Channels
, 2016 Three new zinc diphosphonates possessing bright purple fluorescence, high thermal stability, and an intriguing 3D pillared open framework with 1D 12-member ring channels encapsulating luminescent guest have been rationally designed and synthesized by ...
Ruibiao Fu (1516123) +4 more
core +3 more sources
eJournal of Oral Maxillofacial Research, 2017 Objectives: Osteonecrosis of the jaws is a side effect associated with the use of bisphosphonates. Using histologic analysis, this study aimed to evaluate the influence of microbial colonies in the development of osteonecrosis in the jaws of rats ...
Felipe M. Silveira +3 more
doaj +1 more source
DIPHOSPHONATES IN PAGET'S DISEASE
The Lancet, 1974 Abstract The diphosphonate, sodium etidronate (disodium ethane-1-hydroxy-1,1-diphosphonate) (E.H.D.P.), which inhibits the growth and dissolution of calcium phosphate crystals in vitro, was given at doses of 0, 1, 5, 10, or 20 mg. per kg. per day for up to 6 months to forty-seven patients with Paget's disease of bone.
Russell, R +4 more
openaire +2 more sources
Severe congestive heart failure in elderly patient with Paget’s disease
Geriatric Care, 2017 Paget’s disease of bone is characterized by focal areas of increased bone turnover, affecting one or several bones throughout the skeleton. Paget’s disease is often asymptomatic, but can be associated with bone pain and other skeletal and non-skeletal ...
Lorenzo Palleschi, Eleonora Nunziata
doaj +1 more source
Frontiers in PharmacologyObjectiveThere is currently no consensus on whether the combination therapy of Vitamin D (VitD) and bisphosphonates offers superior efficacy compared to monotherapy in the treatment of postmenopausal osteoporosis.
Yuangui Yang +3 more
doaj +1 more source
World Journal of Nuclear Medicine, 2017 Bone scintigraphy with 99mTc diphosphonates may exhibit extraosseous lesions in addition to metastatic lesions. Multiple factors can affect extraosseous 99mTc methylene diphosphonate (MDP) uptake.
Funda Üstün +3 more
doaj +1 more source
pH‐Responsive Ultrasmall Iron Oxide Nanoassemblies for Activatable T2/T1 Magnetic Resonance Imaging
Advanced NanoBiomed Research, EarlyView.This research reports a pH‐responsive ultrasmall iron oxide nanoparticle (USIONs)/polymer nanoassemblies for activatable magnetic resonance imaging. Amphiphilic diphosphonic acid block copolymers compactly encapsulate USIONs to generate T2‐weighted contrast at physiological pH, while acidic conditions trigger disassembly, activating T1‐weighted ...
Xumin Huang +11 more
wiley +1 more source